Microsoft Word - PD2013_000 - Policy Statement.DOCX - CEC - Document - PDFSEARCH.IO

First Page		Document Content
Date: 2015-03-08 21:29:46 Blood Von Willebrand disease Royal Prince Alfred Hospital Coagulation Bleeding Factor VIII Westmead Hospital Patient safety Haemophilia B Haemophilia Medicine Health		Microsoft Word - PD2013_000 - Policy Statement.DOCX Add to Reading List Source URL: www.cec.health.nsw.gov.au Download Document from Source Website File Size: 484,03 KB Share Document on Facebook

	REGULAR ARTICLE CD4 T cells speciﬁc for factor VIII are present at high frequency in healthy donors and comprise na¨ıve and memory cells ´ ` 1 DocID: 1tX4g - View Document
	News Releases Global Home \| CSL Behring US \| CSL Plasma \| All CSL Behring Web Sites DocID: 1qHpD - View Document
	For immediate release 26 May 2016 AFSTYLA® (rFVIII-Single Chain) – FDA approval CSL Limited (ASX:CSL; USOTC:CSLLY) - CSL today announced that the US Food and Drug Administration (FDA) has approved AFSTYLA® [Antihaemo DocID: 1oCE0 - View Document
	13308 FT Factor VIII Plasma déficient DocID: 1odr2 - View Document
	UPDATE: Baxalta’s BAX 855 Pivotal Data Published in Blood Shows Potential to Provide Strong Bleed Prevention with Twice Weekly Dosing for Patients with Hemophilia A • DocID: 1kAcN - View Document